Hypereosinophilic syndrome
MONDO:0015691Hypereosinophilic syndrome (HES) constitutes a rare and heterogeneous group of disorders, defined as persistent and marked blood eosinophilia and/or tissue eosinophilia associated with a wide range of clinical manifestations reflecting eosinophil-induced tissue/organ damage.
Also known as: HES, hypereosinophilic disease, hypereosinophilic disorder, hypereosinophilic syndrome, eosinophilia
57 clinical trials for this condition and its sub-types, 19 tagged with Hypereosinophilic syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Hypereosinophilic syndrome
-
Pulmonary eosinophilia 30 trials
1 sub-type
-
1 sub-type
-
Secondary hypereosinophilic syndrome 0 trials · 1 incl. sub-types
1 sub-type
-
Eosinophilia-myalgia syndrome 0 trials
-
Primary hypereosinophilic syndrome 0 trials
-
New hope for rare blood disorder: drug targets overactive immune cells
Disease control OngoingThis phase 2 trial is testing the drug ruxolitinib in people with hypereosinophilic syndrome, a rare condition where the body produces too many eosinophils (a type of white blood cell), causing organ damage. The study aims to see if ruxolitinib can normalize blood cell counts and…
Phase 2 • Sponsor: Stanford University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat leukemia
Disease control OngoingThis early-phase trial tests a combination of three drugs—azacitidine, venetoclax, and pevonedistat—in adults newly diagnosed with a challenging form of acute myeloid leukemia (AML). The goal is to find the best dose and see if the combo can improve remission rates. About 40 part…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug aims to tame rare blood disorder flares
Disease control OngoingThis Phase 3 study tests whether benralizumab, a biologic injection given every 4 weeks, can reduce flares in people with hypereosinophilic syndrome (HES), a rare condition where too many eosinophils cause organ damage. About 134 patients aged 12 and older will receive either ben…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Cancer drug shows promise in taming rare blood disorder
Disease control OngoingThis study tests whether the drug imatinib (Gleevec) can safely lower high levels of eosinophils (a type of white blood cell) in people with hypereosinophilic syndrome (HES), a rare condition that can damage organs. About 70 adults and children (age 2 and up) with a specific form…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC